Cala Launches Next-Generation TAPS Wearable Nationwide

SAN MATEO, Calif., October 6, 2026

Cala kIQ Plus Expands Personalized Tremor Therapy

The Cala kIQ Plus System is described as the first and only wearable neuromodulation device offering multiple stimulation waveform modes that users can select or change during treatment. The system provides three stimulation modes, allowing patients to choose the approach they find most suitable for their individual needs. This personalization is supported by findings from a clinical study presented at the 2026 American Academy of Neurology (AAN) Conference, where patients using their preferred waveform demonstrated significantly greater improvement on the Bain and Findley Activities of Daily Living scale compared with traditional waveform stimulation alone. Across the evaluated TAPS therapy modes, the company reported robust, meaningful and statistically significant tremor relief. A majority of patients, ranging from 76% to 89%, achieved at least a one-point reduction in the clinician-rated TETRAS performance score, a measure used to assess tremor severity. These findings support continued development of personalized wearable neuromodulation approaches for people experiencing hand tremor.

Adaptive Calibration Targets Individual Tremor Patterns

A key feature of the Cala kIQ Plus System is its adaptive calibration capability, which is designed to personalize therapy before each treatment session. The technology captures and adjusts to changes in an individual patient’s tremor throughout the day, allowing stimulation to be tailored to the patient’s current condition. The company says this approach is intended to optimize treatment and provide a more intuitive experience for patients using the device regularly. The wearable system also includes three selectable stimulation modes, giving users the ability to switch between therapy options at any time. Cala has designed the system to be fully assembled with on-device guidance to simplify onboarding and daily use. Patients can use the therapy as often as desired throughout the day, subject to the device’s prescribed use and instructions. The technology is particularly relevant for people seeking non-invasive approaches to managing action hand tremor. Cala describes TAPS therapy as a way to bridge treatment approaches between medication and invasive brain surgery by delivering peripheral nerve stimulation through a wearable device.

Nationwide Availability Strengthens MedTech Access

The Cala kIQ Plus System is now available nationwide with a prescription from a healthcare provider, typically a neurologist or movement disorder specialist. Cala is also showcasing the device at the AAN Fall Conference in Las Vegas from October 9–11, 2026, highlighting its latest advances in wearable neuromodulation for movement disorders. The Cala system is available through the Veterans Affairs Health System at no cost to eligible beneficiaries, while Medicare coverage is available for individuals who meet applicable local coverage criteria. The company continues to advocate for additional coverage and reimbursement through Medicare Advantage and commercial payer plans. Cala Health’s broader platform combines neuroscience, wearable technology, peripheral nerve stimulation and digital healthcare delivery to support chronic disease management. The company positions its wearable neuromodulation technology as a way to provide individualized therapy outside traditional clinical settings. With the nationwide launch of Cala kIQ Plus, the company is expanding access to an FDA-cleared technology designed to provide temporary relief of hand tremor symptoms in eligible adults with essential tremor and Parkinson’s disease. The launch represents a significant development in non-invasive wearable neuromodulation and personalized treatment for movement disorders.

Source: Cala Health press release